Keyword: Mirati Therapeutics
Boehringer has moved its pan-KRAS inhibitor into phase 1 trials, both on its own and in combination with Novartis’ MEK inhibitor Mekinist.
The startup posted initial clinical data that suggest MRTX849 can hold its own against Amgen’s rival cancer drug.
The readout is a key moment in the history of the drug and Mirati, shares in which have soared in the updraft created by data on Amgen’s rival asset.
Curis is bringing on board member Robert Martell, formerly CMO at Tesaro, as a full-time employee in the newly created role to head its R&D.